drugset / Trial / NCT00884052

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

NCT00884052

Phase 1/2 Completed 18 enrolled Richard H. Haas Thrasher Research Fund · collab
NaSingle-groupOpen-labelTreatment

Summary

The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.

Timeline

Start
2007-04
Primary completion
2011-03
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 5 mg/kg Intravenous
Subject Levetiracetam Other / unclassified 10 mg/kg Intravenous

Indications